The epidemiology of Her-2/neu and P53 in breast cancer

被引：5
|
作者：
Bernstein, JL [1 ]
López-Carrillo, L [1 ]
Wang, L [1 ]
机构：
[1] CUNY Mt Sinai Sch Med, Dept Community Med, New York, NY 10029 USA
来源：
SALUD PUBLICA DE MEXICO | 1999年 / 41卷
关键词：
breast neoplasms; genes; risk factors; biological markers; racial stocks;
D O I：
10.1590/S0036-36341999000800008
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
Breast cancer is an etiologically heterogeneous disease with marked geographical variations. Joint consideration of the relationship between specific molecular alterations and known or suspected epidemiologic risk factors for this disease should help distinguish subgroups of women that are at elevated risk of developing breast cancer. In this article, we present a comprehensive literature review of the etiologic and prognostic roles of Her-2/neu and P53 among women. In addition,we discuss the advantages and limitations of using biomarkers in epidemiological studies. We conclude that more research is needed to understand the complex relationships between genetic alterations and etiologic risk factors for breast cancer.
引用
收藏
页码：S114 / S123
页数：10
相关论文
共 50 条
  • [1] The molecular epidemiology of breast cancer: HER-2/neu and p53 overexpression among women with breast cancer.
    Bernstein, JL
    Press, M
    Thompson, WD
    Lapinski, R
    Bleiweiss, I
    Zhou, JY
    Schildkraut, J
    Gammon, M
    Haile, R
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 2003, 157 (11) : S9 - S9
  • [2] Predictive value of p53 and Her-2/neu proteins in patients with breast cancer
    不详
    [J]. BREAST, 2005, 14 : S21 - S21
  • [3] p53 and Her-2/neu in juvenile angiofibromas
    Schick, B
    Veldung, B
    Wemmert, S
    Jung, V
    Montenarh, M
    Meese, E
    Urbschat, S
    [J]. ONCOLOGY REPORTS, 2005, 13 (03) : 453 - 457
  • [4] P53 AND HER-2/NEU ARE RARELY IMMUNOHISTOCHEMICALLY DETECTABLE IN MALE BREAST-CANCER
    MIES, C
    MEJIAS, A
    NADJI, M
    MORALES, A
    [J]. LABORATORY INVESTIGATION, 1994, 70 (01) : A19 - A19
  • [5] High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer.
    Sawaki M.
    Ito Y.
    Akiyama F.
    Tokudome N.
    Horii R.
    Mizunuma N.
    Takahashi S.
    Horikoshi N.
    Imai T.
    Nakao A.
    Kasumi F.
    Sakamoto G.
    Hatake K.
    [J]. Breast Cancer, 2006, 13 (2) : 172 - 178
  • [6] Coexpression of her-2/neu and p53 in breast cancer identifies a subset with an aggressive biopathological profile
    Sidoni, Angelo
    Cavaliere, Antonio
    Bellezza, Guido
    Del Sordo, Rachele
    Angiero, Francesca
    Gori, Stefania
    Rulli, Antonio
    Bucciarelli, Emilio
    [J]. TUMORI, 2006, 92 (05) : 412 - 415
  • [7] The efficacy of trastuzumab in Her-2/neu-overexpressing metastatic breast cancer is independent of p53 status
    Köstler, WJ
    Brodowicz, T
    Hudelist, G
    Rudas, M
    Horvat, R
    Steger, GG
    Singer, CF
    Attems, J
    Rabitsch, W
    Fakhrai, N
    Elandt, K
    Wiltschke, C
    Hejna, M
    Zielinski, CC
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2005, 131 (07) : 420 - 428
  • [8] The efficacy of trastuzumab in Her-2/neu-overexpressing metastatic breast cancer is independent of p53 status
    Wolfgang J. Köstler
    Thomas Brodowicz
    Gernot Hudelist
    Margaretha Rudas
    Reinhard Horvat
    Günther G. Steger
    Christian F. Singer
    Johannes Attems
    Werner Rabitsch
    Negar Fakhrai
    Katarzyna Elandt
    Christoph Wiltschke
    Michael Hejna
    Christoph C. Zielinski
    [J]. Journal of Cancer Research and Clinical Oncology, 2005, 131 : 420 - 428
  • [9] p53 and HER-2/neu overexpression in ovarian borderline tumors
    Eltabbakh, GH
    Belinson, JL
    Kennedy, AW
    Biscotti, CV
    Casey, G
    Tubbs, RR
    [J]. GYNECOLOGIC ONCOLOGY, 1997, 65 (02) : 218 - 224
  • [10] P53, Her-2/neu and VEGF determined immunohisochemically in chondrosarcoma
    Kharatishvily, TK
    Stepanova, E
    Mousaev, ER
    Aliev, MD
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2002, : 274 - 274
12345